| 摘要 |
Isolated protein (I) that: (a) has a 647 amino acid (aa) sequence (1), fully defined in the specification; or (b) has, overall, at least 80, preferably 90, % identity or at least 90, preferably 95, % similarity with (1) is new. Independent claims are also included for the following: (1) peptide (Ia) comprising a fragment of (I) with at least 10 aa; (2) variant (Ib) of (1) that includes a mutation that renders the protein dysfunctional; (3) isolated polynucleotide (II), and its fragments, variants or complements, that encode (I)-(Ib); (4) primers for amplification of (II), as RNA or genomic DNA; (5) polynucleotide (IIa) produced by amplification with the primers of (4); (6) method for determining the transcription profile of the gene corresponding to (II) or (IIa); (7) method for detecting other forms of the gene corrresponding to (II) or (IIa); (8) kit for performing methods (6) and (7); (9) cloning and/or expression vector containing (II), (IIa) or their fragments; (10) transformed host cells containing at least one (II), (IIa), their fragments or the vectors of (9); (11) transgenic, non-human organisms in which at least some cells contain at least one (II), (IIa), their fragments or the vectors of (9), in free or integrated forms; (12) preparation of (I)-(Ib) by growing cells of (10) or organisms of (11); (13) protein (Ic) produced by method (12); (14) mono- or poly-clonal antibodies (Ab) that recognize (I)-(Ic) specifically; (15) method for detecting (I)-(Ic) using Ab; (16) in vitro method for evaluating the proliferation capacity or aggressiveness of cancer cells; (17) kit for performing methods (15) or (16); and (18) method of screening for substances that can (a) interact in vitro, directly or indirectly, with (I)-(Ic), (II) or (IIa) or (b) modulate activity of (I)-(Ic). |
